We evaluated short-term response endpoints for acute graft-versus-host disease treatment trials.
Introduction
Allogeneic hematopoietic cell transplantation is frequently complicated by acute graft-versushost disease (GVHD). 1, 2 Three recent studies have evaluated short-term response endpoints after initial treatment of acute GVHD. [3] [4] [5] All three studies were anchored by longer-term mortality and showed that complete response (CR) and traditional partial response (PR) were associated with similar mortality rates. One of these studies examined sensitivity and specificity for predicting 6-month mortality and showed that CR/traditional PR was preferred over CR alone. 4 The authors of all three studies recommended the use of CR/traditional PR at day 28 after initial systemic treatment as an optimal short-term endpoint for clinical trials. [3] [4] [5] Longer-term mortality used as an anchor in previous studies is important in evaluating shortterm response endpoints for acute GVHD, but this outcome represents only one dimension of longer-term outcomes and does not account for subsequent second-line treatment, recurrent malignancy, or the onset of chronic GVHD. [3] [4] [5] [6] [7] [8] The necessity of resorting to second-line treatment with additional systemic agents implies that the initial treatment did not provide the desired benefit and has been considered as treatment failure in evaluating the efficacy of treatment.
Recurrent malignancy should be taken into account, since the risk of relapse could be increased if intensive immunosuppressive treatment diminishes graft-versus-leukemia effects. The onset of chronic GVHD is a competing risk in studies of acute GVHD treatment. Treatment for acute GVHD is not necessarily intended to prevent chronic GVHD, and the onset of chronic GVHD interferes with any subsequent assessment of acute GVHD.
In 2009, a panel of experts proposed a new short-term response category for acute GVHD treatment studies. 9, 10 The panel coined the term "very good partial response" (VGPR) to represent functionally a near complete response and proposed that VGPR might be a more appropriate endpoint than the traditional PR. Traditional PR includes both VGPR and "Other PR" that does not meet criteria for VGPR. VGPR approximates the clinical benefit of CR, since this criterion of response requires near resolution of rash and gastrointestinal abnormalities that are most bothersome to patients with acute GVHD. The panel also proposed that steroid doses at the time of response assessment could be incorporated as part of the primary endpoint in order to enhance the clinical benefit associated with the endpoint.
To investigate these concepts, we conducted a retrospective study among consecutive patients who received initial systemic steroid treatment of acute GVHD at our center. This study had 3 aims: (1) to characterize short-term response categories and longer-term outcomes after initial treatment of acute GVHD, (2) to evaluate the association of short-term response categories with longer-term outcomes, and (3) to examine the merits of incorporating a minimum percent reduction of the initial steroid dose in the response definition.
Methods

Patients
The study cohort included 303 relapse-free adult patients who received initial systemic steroid treatment for grades IIb-IV acute GVHD after a first allogeneic transplantation at the Fred Hutchinson Cancer Research Center / Seattle Cancer Care Alliance between 2000 and 2005.
All patients signed consent forms allowing the use of medical records for research related to outcomes after transplantation, and the institutional review board approved the study.
Definitions
Acute GVHD was prospectively diagnosed, staged and graded according to the established criteria. [11] [12] [13] CR was defined as the complete resolution of acute GVHD manifestations in all organs. Traditional PR was defined as improvement in GVHD stage in at least one of the initially involved organs without complete resolution and without worsening in any other organs. VGPR was retrospectively defined when patients otherwise met the CR criteria but had at least one of the following manifestations (see supplementary Table S1 for details): (1) non-progressive stage 1 rash, not counting residual faint erythema or hyperpigmentation; (2) resolving elevations of total serum bilirubin concentration <25% of baseline; or (3) minimal gastrointestinal symptoms. 10 Other PR was defined as any traditional PR that did not meet criteria for VGPR. No response (NR) was defined as the same stage of GVHD in all organs or progression of GVHD in any organ.
Failure-free survival (FFS) was defined by the absence of 3 types of treatment failure:
second-line systemic treatment for acute GVHD, nonrelapse mortality (NRM) and recurrent malignancy during initial treatment. Second-line treatment was defined as any additional systemic treatment not used for initial treatment of acute GVHD. Second-line treatment also included an increase in steroid dose because of flare during steroid taper. Further details of definitions are available in the Online Supplementary Appendix.
Prophylaxis and treatment of GVHD
GVHD prophylaxis included a calcineurin inhibitor with either methotrexate or mycophenolate mofetil. 13 Prednisone or methylprednisolone was used for initial treatment of acute GVHD. The initial prednisone-equivalent dose was 2 mg/kg/day in majority of patients according to the institutional standard practice and the initial dose was 1 mg/kg/day for some patients at the attending's discretion. 13 After improvement of GVHD manifestations, steroid doses were tapered over 5 to 8 weeks according to the institutional standard practice. Decisions to initiate secondline systemic treatment were made at the discretion of the attending physician.
Statistical analysis
Cumulative incidence estimates of treatment failure defined as the first event of recurrent malignancy, NRM or treatment change during initial treatment were derived, treating each event as a competing risk for the other two. 14 Onset of chronic GVHD during initial treatment was treated as a competing risk for all 3 types of failure. Cox regression and logistic regression models were used to identify factors for treatment failure and day 28 response, respectively.
Sensitivity and specificity analyses were used to evaluate each response definition in predicting the absence of treatment failure at 6 months after initial treatment. Failures before response assessment were included as a NR category. 3, 4 Further details of statistical analysis are available in the Online Supplementary Appendix.
Results
Patient characteristics
The median age of patients in the study cohort was 46 years (range, 18-72 years). One hundred sixty-six (55%) patients had high-risk disease at transplantation, 248 (82%) received a mobilized blood cell graft, 85 (28%) had an HLA-mismatched donor, and 51 (17%) had reduced-intensity conditioning. The median time to initial systemic treatment for acute GVHD was 20 days (range, 5-114 days) after transplantation. At the beginning of systemic treatment, 72 (24%) had grades III-IV acute GVHD, and 233 (77%) were treated initially with prednisone at 2 mg/kg/day. Other characteristics are summarized in Table 1 .
Outcomes after initial systemic treatment of acute GVHD
The cumulative incidences of events after initial systemic treatment of acute GVHD are shown in Figure 1 . In this analysis, only the first events of failure or chronic GVHD were considered, with the bottom area showing the incidence of first failure events and the yellow area showing the incidence of chronic GVHD as a competing risk. Among the 3 components of failure (treatment change, NRM and recurrent malignancy), treatment change was the most frequent cause of failure, while recurrent malignancy and NRM showed similar contributions to failure.
The cumulative incidence of chronic GVHD as a competing risk was 0% at 28 days, 2% at 56 days and 27% at 6 months after initial treatment for acute GVHD. We used day 28 response as the short-term endpoint in further analyses, so that all patients could be evaluated before the onset of chronic GVHD.
Outcomes according to response categories at day 28 after initial treatment
Day 28 response is shown in Figure 2A . failure before day 28. Notably, the cumulative incidence of subsequent chronic GVHD as a competing risk was similar among all response categories (overall P = .14; Figure 2B ). The cumulative incidence of subsequent NRM was higher in patients with NR compared with those in other categories (overall P = .0003; Figure 2C ). The cumulative incidence of NRM was similar among patients with CR, VGPR and Other PR. In contrast, the cumulative incidence of subsequent treatment failure was higher in patients with NR or Other PR compared to those with CR or VGPR (overall P < .0001; Figure 2D ). The cumulative incidence of subsequent treatment failure was similar between patients with CR and VGPR, and between those with
Other PR and NR.
In multivariate analysis ( Outcomes at 6 months among all 303 patients according to response categories at day 28 after initial treatment are shown in Figure 3 . As mentioned above, the proportion of patients with chronic GVHD as a competing risk after initial treatment of acute GVHD was similar among the 4 response categories. The proportions of all 6-month outcomes were closely similar between CR and VGPR. The main difference between VGPR and Other PR was the increased proportion of subsequent treatment change in Other PR compared with VGPR, which decreased the proportion of FFS without chronic GVHD in Other PR compared to VGPR. The main difference between Other PR and NR is the higher proportion of NRM and the lower proportions of treatment change and recurrent malignancy in NR compared with Other PR, while the proportion of FFS without chronic GVHD was similar between these 2 categories.
Correlation of response definitions with absence of failure at 6 months Table 3 summarizes the sensitivity, specificity, and positive and negative predictive values of respective response definitions correlating with absence of failure at 6 months after initial treatment for acute GVHD. These analyses included all 303 patients in order to mimic the interpretation in clinical trials. The loss of sensitivity outweighed the gain of specificity with CR compared to other response definitions, suggesting that CR by itself is too stringent as an endpoint. Specificity was 10% higher for CR/VGPR than for CR/traditional PR, while sensitivity was 10% lower, indicating a balanced trade-off between specificity and sensitivity. In addition, as expected, the burden of residual GVHD manifestations at day 28 after initial treatment is lower in patients with VGPR than in those with Other PR (Supplementary Figure S1 ).
Incorporation of steroid doses into response definition
Among 188 patients with CR/VGPR at day 28 after initial treatment, the median percentage of prednisone dose reduction was 40% (range, -79% to 100%) compared to initial doses. The extent of dose reduction was closely similar between patients treated initially with 1 mg/kg/day and those with 2 mg/kg/day (median, 40% vs. 40%; P = .73). 
Factors associated with CR/VGPR at day 28 after initial treatment
Multivariate logistic regression models identified two factors associated with lower rates of CR/VGPR at day 28 after initial treatment: the use of an unrelated or HLA-mismatched related donor compared with the use of an HLA-matched related donor, and liver or GI involvement at initial treatment (Supplementary Table S2 ). Rates of CR/VGPR at day 28 were 82% in 17 patients with neither risk factor, 74% in 139 patients with one risk factor, and 48% in 147 patients with both risk factors. Patient age, patient sex, disease risk, graft source, conditioning intensity, gender matching, GVHD prophylaxis, GVHD grade at initial treatment, time from transplantation to initial treatment, and initial dose of steroids were not associated with day 28 CR/VGPR.
DISCUSSION
This study differs from previous studies in four major ways. First, we examined all 3 components of treatment failure, in addition to nonrelapse mortality (NRM), in assessing the relationship between response categories and longer-term outcomes. In this analysis, we categorized treatment change, recurrent malignancy and NRM as failures and chronic GVHD as a competing risk. Second, we assessed VGPR and Other PR separately in order to distinguish differences in the symptom burden at day 28 after initial treatment and to characterize differences in the relationship between these categories and subsequent outcomes. 10 Third, we examined the overall trade-off between sensitivity and specificity of response definitions in predicting longer-term outcomes, giving priority to specificity in order to decrease the falsepositive rate (type-1 error). Fourth, we assessed the merit of incorporating a minimum percent reduction of the steroid dose as an additional criterion of response.
Our results support the use of CR/VGPR at day 28 after initial treatment as a short-term endpoint at least for 4 reasons. First, most patients can be evaluated at the transplant center at day 28. Moreover, none of the patients in our study developed chronic GVHD before day 28.
Second, the rate of subsequent treatment failure was equivalent between CR and VGPR, but was lower than for Other PR or NR. Third, as expected, the symptom burden at day 28 was lower in patients with VGPR as compared to those with Other PR. Fourth, CR itself was too stringent to serve as an endpoint because the loss of sensitivity outweighed the gain of specificity compared to CR/VGPR in predicting the absence of failure at 6 months.
Describing the 3 causes of treatment failure together with onset of chronic GVHD helped to interpret the results in this study. 15 Our results showed that 22% of patients initiated second-line treatment within 6 months and that systemic treatment change was the most frequent category of failure after initial treatment of acute GVHD. Smaller proportions had NRM or recurrent malignancy as reasons for treatment failure. The results shown in Figure 1 provide a useful point of comparison for future acute GVHD treatment studies.
Treatment failure after day 28 was predicted by older patient age, grades III-IV GVHD at initial treatment and responses less than VGPR at day 28. The associations of these factors with mortality have been reported in previous studies. [3] [4] [5] Previous studies showed that disease risk, HLA matching, donor relationship and liver involvement at initial treatment were associated with mortality, 3, 4, 16 but they were not associated with treatment failure in our study. The use of an unrelated donor or HLA-mismatched related donor and involvement of the liver or gut were associated with a lower probability of CR/VGPR at day 28 after initial treatment, consistent with the results of previous studies. [6] [7] [8] Consideration of these risk factors would help to interpret the results of other clinical studies.
The selection of day 28 after initial treatment as the time point for response assessment in our study is consistent with the 3 previous studies that have investigated endpoints for acute GVHD treatment trials. [3] [4] [5] Assessment at later time points is likely to be complicated by events that are not necessarily related to failure of acute GVHD treatment. In our analysis, we elected to treat chronic GVHD as a competing risk, since events after the onset of chronic GVHD are not necessarily related to prior acute GVHD or its treatment. These considerations make it difficult to assign outcomes as either success or failure in patients who develop chronic GVHD before the time point for response assessment. We found that patients started to develop chronic GVHD before day 56, and 27% of the patients developed chronic GVHD by 6 months after initial treatment, but no patients developed chronic GVHD before day 28. By assessing response at day 28, all patients could be evaluated before the onset of chronic GVHD.
As in previous studies, our results showed that CR, VGPR and Other PR at day 28 were associated with similar subsequent NRM. [3] [4] [5] In contrast, the cumulative incidence of treatment failure showed important differences between VGPR and Other PR. This difference was explained by the lower proportion of treatment change in patients with VGPR than in those with Other PR. The cumulative incidence of treatment failure was similar in the VGPR group compared to CR group. Likewise, the cumulative incidence of treatment failure was similar in the Other PR group compared to the NR group. In addition, by definition, patients with VGPR have a minimal symptom burden, whereas those with Other PR can have a significant residual symptom burden. These comparisons emphasize the importance of distinguishing VGPR from
Other PR both in clinical trials and clinical practice.
Even for patients with CR/VGPR, prolonged treatment with high-dose steroids can cause many adverse effects. 17 We therefore evaluated whether a minimum reduction of the initial steroid dose should be incorporated as part of the response definition at day 28 after initial treatment. In this analysis, patients with CR/VGPR and dose reduction less than the threshold are categorized as non-responders. In our study, 19% of patients with CR/VGPR at day 28 did not reduce steroid doses by ≥ 30% of the initial dose. Reclassification of these patients as nonresponders decreased the false-positive rate by 9% in predicting absence of failure at 6 months.
On the other hand, the distribution of 6-month outcomes among patients with CR/VGPR did not show major differences between those with ≥ 30% reduction in the steroid dose compared to those with <30% reduction. This similarity contrasts with the large difference in outcomes between patients with VGPR compared to those with Other PR. We conclude that incorporating a minimum percent reduction of the initial steroid dose has some but limited value in the definition of response at day 28 after initial treatment for acute GVHD.
Some investigators might want to consider recurrent malignancy as a competing risk or chronic GVHD as treatment failure. The importance of distinguishing between VGPR and Other PR remained the same even if different definitions were applied (Supplementary Figure S2) .
This was also supported by the results shown in Figure 3 , since proportions of 6-month outcomes remained the same regardless of definitions of these events. Because initial treatment can diminish graft-versus-leukemia effects, we recommend that recurrent malignancy be considered as treatment failure in clinical trials. As shown in Figure 2B , incidence rates of chronic GVHD were similar among all response categories at day 28, indicating that effective treatment of acute GVHD does not necessarily have an influence on risk of chronic GVHD. In addition, the onset of chronic GVHD makes any subsequent events difficult to interpret from the perspective of evaluating initial treatment benefit. Thus, we recommend considering chronic GVHD as a competing risk in clinical trials.
The current study has some limitations. First, systemic treatment change and rates of steroid reduction must be carefully interpreted because both factors are controlled by providers. The value of these factors could be improved by including standardized guidelines for adding second-line treatment and for tapering steroid doses. In clinical practice, strict control of steroid taper is difficult to enforce because patient conditions might not allow the pre-scheduled taper.
Second, the study cohort includes only adult patients who received marrow or growth factormobilized blood cells, and the results might not apply to pediatric patients or cord blood transplantation. Third, 24% of our patients were treated initially with prednisone at 1 mg/kg/day, an approach that remains under investigation at our center. The aim of the current study, however, was to examine the relationship between response categories and longer-term outcomes regardless of the initial steroid dose. In fact, initial steroid dose was not associated with CR/VGPR at day 28 or with subsequent treatment failure. In addition, the conclusions held true when analyses were limited to patients treated initially with 2 mg/kg/day (results not shown).
Lastly, the results were drawn from retrospective data at a single center. Further prospective and retrospective studies are warranted to determine whether findings from this study can be generalized.
This study highlights some challenges in defining the primary endpoint in acute GVHD treatment trials. Short-term response categories are poor surrogates for longer-term outcomes in patients with acute GVHD, as demonstrated by low sensitivity and specificity in predicting 6-month outcomes in this study and in previous studies. [3] [4] [5] At the same time, longer-term outcomes cannot be used as primary endpoints, due to the difficulty of interpreting results in patients who develop chronic GVHD. These inescapable shortcomings apply to all endpoints used in acute GVHD treatment trials. Nonetheless, our analysis clearly indicates that response categories in acute GVHD treatment trials should distinguish between VGPR and Other PR. Our results support the use of CR/VGPR at day 28 after initial treatment as an appropriate shortterm endpoint in acute GVHD treatment trials.
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Definitions
Acute GVHD was prospectively diagnosed, staged and graded according to the established criteria. 3, 4 Grade IIa GVHD was defined as stage 1 gastrointestinal (GI) involvement with stage 0-2 skin involvement and no liver involvement. Grade IIb GVHD was defined as stage 3 skin involvement or stage 1 liver involvement with or without stage 1 GI involvement. 5 The intensity of conditioning regimens was defined as high-intensity or reduced-intensity as described elsewhere. 5, 6 CR was defined as the complete resolution of acute GVHD manifestations in all organs. Traditional PR was defined as improvement in GVHD stage in at least one of the initially involved organs without complete resolution and without worsening in any other organs. VGPR was retrospectively defined through detailed chart review when patients otherwise met the CR criteria but had at least one of the following manifestations (see Supplementary Table S1 for additional details): (1) non-progressive stage 1 rash, not counting residual faint erythema or hyperpigmentation; (2) resolving elevations of total serum bilirubin concentration <25% of baseline; (3) minimal GI symptoms as defined by tolerance of oral intake, predominantly formed stools, no abdominal cramping, and no more than occasional nausea or vomiting. 7 Other PR was defined as any traditional PR that did not meet criteria for VGPR. No response (NR) was defined as the same stage of GVHD in all organs or progression of GVHD in any organ. Chronic GVHD was diagnosed according to the National Institutes of Health consensus criteria. 
Prophylaxis and treatment of GVHD
GVHD prophylaxis included a calcineurin inhibitor with either methotrexate or mycophenolate mofetil (MMF) after high-intensity conditioning, and a calcineurin inhibitor and MMF after reduced-intensity conditioning. 5 Prednisone or methylprednisolone was used for initial treatment of acute GVHD. The initial prednisone-equivalent dose was 2 mg/kg/day in majority of patients according to the institutional standard practice and the initial dose was 1 mg/kg/day for some patients at the attending's discretion. 5 Daily prednisone doses >1.0 mg/kg/day were given in divided doses twice daily, while lower doses were given once daily in the morning. After improvement of GVHD manifestations, steroid doses were tapered over 5 to 8 weeks according to the institutional standard practice. Decisions to initiate second-line systemic treatment were made at the discretion of the attending physician.
Statistical analysis
Cumulative incidence estimates of treatment failure defined as the first event of recurrent malignancy, NRM or systemic treatment change during initial treatment were derived, treating each event as a competing risk for the other two. 10 Onset of chronic GVHD during initial treatment was treated as a competing risk for all 3 types of failure. Cumulative incidence estimates of NRM were also derived, treating recurrent malignancy as the only competing risk.
Cox regression models were used to identify risk factors for treatment failure. Logistic regression models were used to identify factors associated with day 28 response. Covariates included were patient age at transplantation (per decade), patient sex, donor-patient gender combination, disease risk, graft source, HLA matching, donor relation, intensity of conditioning regimen, GVHD prophylaxis, GVHD grade at initial treatment, organ involvement at initial treatment (any skin vs. no skin, any liver vs. no liver, any GI tract vs. no GI, or skin only vs.
others), time from transplantation to initial treatment for acute GVHD (>20 days vs. ≤20 days) and initial dose of steroids. Factors having a likelihood ratio P-value ≤.05 for association with failure in univariate testing were included in a multivariate model. A backward elimination procedure was used to exclude risk factors until the P-value of the likelihood ratio test for all remaining risk factors was ≤.05.
Sensitivity and specificity analyses were used to evaluate each response definition in predicting the absence of treatment failure at 6 months after initial treatment. Positive and negative predictive values were also calculated. As in previous studies, 11, 12 failures before response assessment were included as a NR category in these analyses in order to correspond to the conduct and interpretation of clinical trials. The 6-month time point for assessing longerterm outcomes was used for consistency with previous studies. 11, 13 Plots of sensitivity and specificity were examined to evaluate the merits of incorporating a minimum percent reduction of the initial steroid dose in the response definition.
Interpretation of sensitivity and specificity
Sensitivity denotes the proportion of short-term responders among patients without longer-term treatment failure. Low sensitivity indicates a high incidence of false-negative results (type 2 error). Specificity denotes the proportion of short-term non-responders among patients with longer-term treatment failure. Low specificity indicates a high incidence of false-positive results (type 1 error). Clinical trials have less tolerance for false-positive results than for false-negative results. Therefore, specificity was prioritized over sensitivity when sensitivity and specificity showed a balanced trade-off.
Supplementary Table S1. Detailed definition of VGPR
Skin
The terminology allows active erythematous rash involving <25% of the body surface area. Rash that is pink, fading, or turning to brown is not included in the measurement, because these findings indicate resolving lesions.
Liver
The terminology allows for persisting low level hyperbilirubinemia that might be related to antecedent regimen-related hepatotoxicity, concomitant hemolysis, or administration of hepatotoxic agents such as voriconazole, cyclosporine, or total parental nutrition (TPN), or other factors such as sepsis. A serum total bilirubin concentration of <2 mg/dL approximates normal values, and a reduction to <25% of the baseline concentration provides strong evidence of progression toward normal liver function among patients with levels ≥2 mg/dL.
Gut
Criteria in the terminology were selected to indicate that gut function and water resorption in the colon are approaching normal. These criteria have some imprecision and rely heavily on patient recall, rather than measurement of stool volume, but they can be easily used for outpatients. In certain cases, it might be necessary to make allowances for the effects of pretransplant diseases that cause diarrhea. 
